ISSN 1671-5411 CN 11-5329/R
Aaqib H Malik, Syed Zaid, Hasan Ahmad, Joshua Goldberg, Tanya Dutta, Cenap Undemir, Martin Cohen, Wilbert S Aronow, Steven L Lansman. A meta-analysis of 1-year outcomes of transcatheter versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis. J Geriatr Cardiol 2020; 17(1): 43-50. doi: 10.11909/j.issn.1671-5411.2020.01.005
Citation: Aaqib H Malik, Syed Zaid, Hasan Ahmad, Joshua Goldberg, Tanya Dutta, Cenap Undemir, Martin Cohen, Wilbert S Aronow, Steven L Lansman. A meta-analysis of 1-year outcomes of transcatheter versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis. J Geriatr Cardiol 2020; 17(1): 43-50. doi: 10.11909/j.issn.1671-5411.2020.01.005

A meta-analysis of 1-year outcomes of transcatheter versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis

doi: 10.11909/j.issn.1671-5411.2020.01.005
Funds:

None

  • Received Date: 2019-10-06
  • Rev Recd Date: 2019-10-06
  • Publish Date: 2020-01-28
  • Background Transcatheter aortic valve replacement (TAVR) for the treatment symptomatic severe aortic stenosis (AS) is indicated in patients with intermediate or higher surgical risk. Latest trials showed TAVR, and surgical aortic valve replacement (SAVR) perform similarly at 1-year for the composite outcomes of mortality, stroke and rehospitalization. We performed a comprehensive meta-analysis to compare individual outcomes at 1-year for TAVR compared to SAVR in low-risk patients. Methods PubMed, Embase, and Cochrane central were searched for all the randomized controlled trials (RCTs) that reported 1-year comparative outcomes of TAVR and surgical aortic valve replacement (SAVR). Our conclusions are based upon the random-effects model using DerSimonian-Laird estimator. Results Data from 4 trials and 2887 randomized patients showed that TAVR had lower rates of all-cause mortality, cardiovascular mortality, and atrial fibrillation compared to SAVR at 1-year follow-up (P P Conclusions The latest randomised trial data demonstrates that in short-term, TAVR is safe and effective in reducing all-cause mortality or stroke. Longer follow-up of RCTs is needed to determine the durability of clinical benefits in TAVR over SAVR in low-risk patients.
  • loading
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (483) PDF downloads(395) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return